Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 10/20 | 0.57 |
| ▸ | LMNA | P02545 | 10/20 | 0.55 |
| ▸ | TP53 | P04637 | 8/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15847595 | 1.00 | KMT2A (0.63) | KMT2AMAPTLMNATP53RECQL | |
| SCHEMBL15847593 | 1.00 | KMT2A (0.63) | KMT2AMAPTLMNATP53RECQL | |
| SCHEMBL15847362 | 0.90 | MAPT (0.56) | KMT2AMAPTLMNATP53RECQL | |
| SCHEMBL15847989 | 0.90 | KMT2A (0.66) | KMT2AMAPTLMNATP53RECQL | |
| SCHEMBL29369833 | 0.90 | KMT2A (0.66) | KMT2AMAPTLMNATP53RECQL | |
| SCHEMBL29354976 | 0.90 | KMT2A (0.66) | KMT2AMAPTLMNATP53RECQL | |
| SCHEMBL15848170 | 0.90 | KMT2A (0.66) | KMT2AMAPTLMNATP53RECQL | |
| SCHEMBL14487951 | 0.90 | KMT2A (0.66) | KMT2AMAPTLMNATP53RECQL | |
| SCHEMBL15847487 | 0.87 | POLB (0.64) | KMT2AMAPTLMNATP53RECQL | |
| SCHEMBL15847582 | 0.87 | POLB (0.64) | KMT2AMAPTLMNATP53RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| CN-105209031-A | Novel antiviral agents against HBV infection | UNIV DREXEL | 2015-12-30 | — | — | CN | disclosed |
| EP-2938338-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | Drexel University (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014106019-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL (US) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, EIF2AK2, NR1H4 | KMT2A 3874/4885MAPT 4494/4885LMNA 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.